Skip to main content

Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study

Buy Article:

$36.50 + tax (Refund Policy)


Although clinical trials documented omalizumab's efficacy in U.S. patients with chronic idiopathic urticaria (CIU), the real-world evidence on its long-term effectiveness is lacking.


To assess omalizumab use and the long-term response in a large sample of U.S. real-world patients.


Patients with CIU and ≥ 12 years old who were initiated on omalizumab (index date) and with ≥ 6 months of postindex data were identified in an electronic medical record system (2007‐2018). Omalizumab use was described. Provider assessments of disease control and course, and patient-reported symptoms were compared at 6-month intervals postindex versus baseline in the patients with values available at both time points.


A total of 1096 patients (mean age, 44.1 years; 74.7% women) were followed up for a mean of 19 months postindex. Patients, predominantly initiated on a 300-mg dose, received a mean of 15 omalizumab administrations and were treated continuously for a mean of 14.2 months. At 6 months postindex versus baseline, the patients (n = 708) were more likely to be well controlled (odds ratio [OR] 31.68 [95% confidence interval {CI}, 17.20‐58.36]) with an improved disease course (OR 15.73 [95% CI, 11.33‐21.85]). Moreover, the patients (n = 373) were less likely to report itching (OR 0.39 [95% CI, 0.21‐0.76]), rash (OR 0.59 [95% CI, 0.45‐0.78]), and swelling (OR 0.46 [95% CI, 0.36‐0.59]). Benefits associated with omalizumab treatment were sustained through month 24 and beyond.


This real-world study showed that the patients who received a mean of 15 omalizumab administrations over a mean of 14.2 months experienced, starting at 6 and through 24 months after omalizumab initiation and beyond, improved CIU control, course, and symptoms.

Keywords: Chronic idiopathic urticaria; chronic spontaneous urticaria; disease control; disease course; electronic medical records; omalizumab; provider assessment; real-world evidence; treatment patterns; treatment response

Document Type: Research Article

Affiliations: 1: From the Novartis Pharmaceutical Corporation, East Hanover, New Jersey 2: Analysis Group, Inc., Montréal, Québec, Canada 3: Allergy Partners P.A., Asheville, North Carolina 4: Allergy Partners of San Diego, San Diego, California

Publication date: September 1, 2019

This article was made available online on July 25, 2019 as a Fast Track article with title: "Long-term omalizumab outcomes in chronic idiopathic urticaria: A real-world study".

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Commercial level: Permission to use content
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content